Corrigendum to "Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study" [Clinical Therapeutics 40 (12) (2018) 2077-2087].

Authors

Kiren Kresa-Reahl, Providence Multiple Sclerosis Center, USA.Follow
P Repovic, Multiple Sclerosis Center (P.R., A.M., P.Q., L.K.J.H., B.G., J.D.B.), Swedish Neuroscience Institute, Seattle, WashingtonFollow
Derrick Robertson
Macaulay Okwuokenye
Leslie Meltzer
Jason P Mendoza

Document Type

Article

Publication Date

6-26-2019

Publication Title

Clinical therapeutics

Clinical Institute

Neurosciences (Brain & Spine)

Department

Neurosciences

Recommended Citation

Kresa-Reahl, Kiren; Repovic, P; Robertson, Derrick; Okwuokenye, Macaulay; Meltzer, Leslie; and Mendoza, Jason P, "Corrigendum to "Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study" [Clinical Therapeutics 40 (12) (2018) 2077-2087]." (2019). Articles, Abstracts, and Reports. 1918.
https://digitalcommons.providence.org/publications/1918